andexanet alfa

E241384

Andexanet alfa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.

All labels observed (1)

Label Occurrences
andexanet alfa canonical 11

How this entity was disambiguated

Statements (50)

Predicate Object
instanceOf antidote ⓘ
biologic drug ⓘ
coagulation factor Xa decoy protein ⓘ
reversal agent for factor Xa inhibitors ⓘ
approvalYear 2018 ⓘ
approvedBy European Medicines Agency ⓘ
U.S. Food and Drug Administration ⓘ
belongsToClass anticoagulant reversal agents ⓘ
hemostatic agents ⓘ
countryApprovedIn European Union ⓘ
United States ⓘ
derivedFrom human factor Xa ⓘ
developedBy Alexion Pharmaceuticals ⓘ
Portola Pharmaceuticals ⓘ
hasAdverseEffect cardiac arrest ⓘ
infusion-related reactions ⓘ
ischemic stroke ⓘ
myocardial infarction ⓘ
pneumonia ⓘ
thromboembolic events ⓘ
urinary tract infection ⓘ
hasATCCode V03AB38 ⓘ
hasBlackBoxWarning thromboembolic risk ⓘ
hasContraindication known hypersensitivity to andexanet alfa ⓘ
hasDosageForm intravenous solution ⓘ
hasGenericName andexanet alfa ⓘ
hasIndication reversal of anticoagulation due to apixaban ⓘ
reversal of anticoagulation due to rivaroxaban ⓘ
treatment of life-threatening bleeding in patients on factor Xa inhibitors ⓘ
treatment of uncontrolled bleeding in patients on factor Xa inhibitors ⓘ
hasMolecularTarget apixaban ⓘ
betrixaban ⓘ
linked to: Xarelto

coagulation factor Xa ⓘ
edoxaban ⓘ
enoxaparin ⓘ
rivaroxaban ⓘ
linked to: Xarelto
hasTradeName Andexxa ⓘ
Ondexxya ⓘ
hasUNII 9Z8WZ3Z3PO ⓘ
isExpensive true ⓘ
isModifiedProtein true ⓘ
isRecombinant true ⓘ
legalStatusEU prescription only ⓘ
legalStatusUS prescription only ⓘ
mechanismOfAction acts as a decoy factor Xa that binds factor Xa inhibitors ⓘ
restores thrombin generation ⓘ
reverses anticoagulant effects of factor Xa inhibitors ⓘ
pharmacokineticProperty rapid onset of action ⓘ
short half-life ⓘ
routeOfAdministration intravenous ⓘ

How these facts were elicited

Referenced by (11)

Full triples — surface form annotated when it differs from this entity's canonical label.

Xarelto → hasAntidote → andexanet alfa ⓘ
andexanet alfa → hasGenericName → andexanet alfa ⓘ
apixaban → hasAntidote → andexanet alfa ⓘ
Andexxa → hasGenericName → andexanet alfa ⓘ
Andexxa → hasNonproprietaryName → andexanet alfa ⓘ
Andexxa → hasINN → andexanet alfa ⓘ
Ondexxya → hasActiveIngredient → andexanet alfa ⓘ
Ondexxya → hasINN → andexanet alfa ⓘ
Portola Pharmaceuticals → developed → andexanet alfa ⓘ
DOAC → hasReversalAgent → andexanet alfa ⓘ